Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

FDA approved pembrolizumab for chemotherapy-refractory r/m cervical cancer with PD-L1 CPS ≥1 

/0 Comments/in , , , , , /by

 

You might also like
ESMO 2016 nivolumab data medipaper medical communications ESMO16 Nivolumab data – Download the PPT
Pembrolizumab plus pemetrexed-platinum approved for use in the 1st-line treatment of metastatic non-squamous NSCLC Lenvatinib FDA approved for 1st-line treatment of HCC
FDA approves avelumab plus axitinib for renal cell carcinoma
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency Obinutuzumab plus chemotherapy FDA approved for follicular lymphoma
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency FoundationOne companion diagnostic FDA approved
JAVELIN Lung 200 avelumab vs docetaxel in patients with pretreated advanced non-small cell lung cancer NSCLC JAVELIN Lung 200: avelumab vs docetaxel for pretreated NSCLC
Blood-based TMB-assay predicts response to atezolizumab in NSCLC patients Plasma TMB predicts response to atezolizumab in NSCLC patients
Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply